Two China biotechs drop U.S. IPO plans for $800 million Hong Kong floats: sources

Innovent declined to comment on its IPO plans. The two companies chose Hong Kong because … Innovent and Ascentage will be following Shanghai Henlius Biotech, backed by Chinese conglomerate Fosun International, diabetes-focused drug developer Hua Medicine …
( read original story …)

Related Post